Integrative network pharmacology and experimental validation identify Taglisodog-eum (TLSD) as a modulator of intestinal barrier integrity and STAT6/STAT3-related inflammatory responses in inflammatory bowel disease

Background Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal disorder characterized by immune dysregulation and epithelial barrier disruption. Although conventional therapies are widely used, their clinical application is often limited by adverse effects. The herbal formula Taglisodog-eum (TLSD), composed of eleven medicinal herbs, including Panax ginseng and Astragalus membranaceus, may serve as a promising multi-target alternative. Methods We integrated LC-ESI-QTOF-MS/MS chemical profiling, network pharmacology, and experimental validation to elucidate the therapeutic mechanisms of TLSD. Bioactive compounds and disease targets were screened via TCMSP, BATMAN-TCM, and DisGeNET databases. Protein-protein interaction (PPI) and KEGG pathway analyses identified core targets and signaling hubs. Validation was performed using Jurkat T cells via cytokine transcription and STAT3/6 signaling, and Caco-2 epithelial cells via wound healing and tight junction expression. Results LC-MS analysis identified 44 major bioactive markers, including ginsenosides, astragalosides, and flavonoids. Network pharmacology revealed 102 overlapping targets between TLSD and IBD, with STAT3, TNF, RELA, SRC, and TGFB1 identified as core nodes. Molecular docking confirmed stable binding (energy < −5 kcal/mol) between these core proteins and TLSD constituents like luteolin, calycosin, α-amyrin, and quercetin. In vitro , TLSD (0.1–1 μg/mL) exerted a dose-dependent suppression of Th2 (IL-4, IL-5, IL-10, IL-13) and Th17 (IL-17, IL-22) cytokine signatures. Furthermore, it significantly promoted epithelial wound healing and upregulated the tight junction markers ZO-1 and Claudin-4. Mechanistically, TLSD effectively inhibited the phosphorylation of STAT6 and STAT3, disabling critical pathways for inflammatory cytokine production. Conclusion This study revealed that TLSD acts as a multi-component therapeutic agent that restores intestinal homeostasis by enhancing epithelial barrier integrity and broadly repressing T-cell mediated inflammatory signaling. This study provides a mechanistic framework supporting TLSD as a potential multi-target strategy for IBD management. However, while these multi-component formulations offer holistic multi-target potential, their further preclinical investigation remains constrained by inherent limitations, including low oral bioavailability, complex in vivo metabolic fates, and potential herb-drug interactions, which require further pharmacokinetic and in vivo investigation.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.3389/fphar.2026.1909247
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrative network pharmacology and experimental validation identify Taglisodog-eum (TLSD) as a modulator of intestinal barrier integrity and STAT6/STAT3-related inflammatory responses in inflammatory bowel disease

Mi Hye Kim, Young‐Won Chin, Minh Nhat Tran, Myung‐Ho Kim et al.
4 links
Frontiers in Pharmacology
Inflammatory Bowel Disease
article

Integrative network pharmacology and experimental validation identify Taglisodog-eum (TLSD) as a modulator of intestinal barrier integrity and STAT6/STAT3-related inflammatory responses in inflammatory bowel disease

Mi Hye Kim, Young‐Won Chin, Minh Nhat Tran, Myung‐Ho Kim, Chan-Woong Park, My-Le Nguyen-Thi
article en

Abstract

Background Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal disorder characterized by immune dysregulation and epithelial barrier disruption. Although conventional therapies are widely used, their clinical application is often limited by adverse effects. The herbal formula Taglisodog-eum (TLSD), composed of eleven medicinal herbs, including Panax ginseng and Astragalus membranaceus, may serve as a promising multi-target alternative. Methods We integrated LC-ESI-QTOF-MS/MS chemical profiling, network pharmacology, and experimental validation to elucidate the therapeutic mechanisms of TLSD. Bioactive compounds and disease targets were screened via TCMSP, BATMAN-TCM, and DisGeNET databases. Protein-protein interaction (PPI) and KEGG pathway analyses identified core targets and signaling hubs. Validation was performed using Jurkat T cells via cytokine transcription and STAT3/6 signaling, and Caco-2 epithelial cells via wound healing and tight junction expression. Results LC-MS analysis identified 44 major bioactive markers, including ginsenosides, astragalosides, and flavonoids. Network pharmacology revealed 102 overlapping targets between TLSD and IBD, with STAT3, TNF, RELA, SRC, and TGFB1 identified as core nodes. Molecular docking confirmed stable binding (energy < −5 kcal/mol) between these core proteins and TLSD constituents like luteolin, calycosin, α-amyrin, and quercetin. In vitro , TLSD (0.1–1 μg/mL) exerted a dose-dependent suppression of Th2 (IL-4, IL-5, IL-10, IL-13) and Th17 (IL-17, IL-22) cytokine signatures. Furthermore, it significantly promoted epithelial wound healing and upregulated the tight junction markers ZO-1 and Claudin-4. Mechanistically, TLSD effectively inhibited the phosphorylation of STAT6 and STAT3, disabling critical pathways for inflammatory cytokine production. Conclusion This study revealed that TLSD acts as a multi-component therapeutic agent that restores intestinal homeostasis by enhancing epithelial barrier integrity and broadly repressing T-cell mediated inflammatory signaling. This study provides a mechanistic framework supporting TLSD as a potential multi-target strategy for IBD management. However, while these multi-component formulations offer holistic multi-target potential, their further preclinical investigation remains constrained by inherent limitations, including low oral bioavailability, complex in vivo metabolic fates, and potential herb-drug interactions, which require further pharmacokinetic and in vivo investigation.

Frontiers in PharmacologyVol. 17
Seoul National University (KR), Jaseng Medical Foundation (KR), Huế University of Medicine and Pharmacy (VN), Woosuk University (KR)
National Research Foundation, Ministry of Science and ICT, South Korea
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon